| 8.34 -0.97 (-10.42%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.38 | 1-year : | 15.67 |
| Resists | First : | 10.6 | Second : | 13.42 |
| Pivot price | 8.39  |
|||
| Supports | First : | 6.05 | Second : | 5.03 |
| MAs | MA(5) : | 8.9 |
MA(20) : | 8.32 |
| MA(100) : | 9.04 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 37 |
D(3) : | 39.4 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 30.25 | Low : | 6.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MTVA ] has closed above bottom band by 48.9%. Bollinger Bands are 35% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.39 - 9.44 | 9.44 - 9.48 |
| Low: | 8.1 - 8.16 | 8.16 - 8.21 |
| Close: | 8.26 - 8.35 | 8.35 - 8.42 |
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Fri, 05 Dec 2025
MetaVia Inc. (MTVA) Stock Jumps After Reverse Split: What the New Price, Trial Data and 2026 Forecast Mean for Investors - ts2.tech
Tue, 02 Dec 2025
MetaVia (Nasdaq: MTVA) enacts 1-for-11 reverse split, cuts shares to 2.3M from 25.4M - Stock Titan
Tue, 02 Dec 2025
MetaVia announces 1-for-11 reverse stock split effective December 4 - Investing.com
Tue, 02 Dec 2025
MetaVia Inc. Announces 1-for-11 Reverse Stock Split - PR Newswire
Mon, 10 Nov 2025
MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025… - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 62.5 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 2 (K) |
| EPS | -10.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.5 % |
| Return on Equity (ttm) | -168.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.8 |
| PEG Ratio | 0 |
| Price to Book value | 2.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|